Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is Steen's challenge in the UK.
https://www.bbc.co.uk/news/health-64251636
Nor me - I keep checking. Must be soon surely.
...Nope. Nothing here yet either colorblind86. I'm not worried though. Won't be selling just yet methinks (can't yet anyway)
Anyone got their shares registered yet?
Still no sign my end!
oops meant to add this link (as quoted in article - but US and Canada home page)
https://aeprobio.com/
haven't time to pursue further this evening
mol
Hardly an endorsing review overall - but at least no direct reference to us - optibac and others can't be too pleased mind
https://www.which.co.uk/reviews/nutrition-and-supplements/article/probiotics-and-gut-health-what-you-should-know-ank9n5F5VzfQ
though several references to ibs (seed as we know have a trial awaiting results) and vsl3
There is some evidence for probiotics helping IBS, but it may not work for everyone. Some products that have published studies in relation to IBS include Alflorex, BioKult Advanced, Symprove and VSL3.
https://optibiotix.com/probiotix-health-announces-major-apac-distribution-deal-with-actial-farmaceutica-for-cholbiome/
https://www.vsl3.co.uk/
confirmed again in admission document
In July 2020, ProBiotix entered into a non-exclusive distribution agreement with Actial Farmaceutica Srl
(“Actial”) for the distribution of CholBiome® and CholBiome®X3 into the Asia Pacific region as a
cardiovascular extension to Actial’s VSL#3® brand, widely regarded as one of the world’s best known
probiotic brands.
https://probiotixhealth-ir.com/docs/probiotixhealthlibraries/archive/admission-document.pdf
Steen has his targets for 2023 but improving the website (to include various media reports etc - eg radio 4 earlier in year) woud be a very simple and inexpensive start
mol
*************+74S_bEyNGV4yYzM0
as noted in update we have three abstracts accepted at undernoted coming event next month
https://probiotaevent.com/live/en/page/programme
you'll note a number of the sponsors at bottom of page are well known to us and us to them
with this panel responsible for abstracts - either accepting or denying same
https://probiotaevent.com/live/en/page/scientific-frontiers-2023
and finally
speakers include Prof Tim Spector who is/or at least was a member of our Scientific Advisory Group
https://www.optibiotix-ir.com/content/news/ir_news/19-01-16
mol
update here re monocolin K and further restrictions in EU
https://www.sandwalkbio.com/post/monacolins-restrictions-coming-up-in-europe
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32022R0860
and cholbiomex3 out of stock has now slipped to Mar 23 from Feb 23 - perhaps to adjust to EU new regs?
https://optibiotix.online/products/cholbiomex3
as aquae noted elsewhere contains the equivalent of 10mg Monocolin K
Supplement Facts
Serving Size: 1 Tablet, Servings Per Container: 30 Per Tablet %NRV*
Red Yeast Rice 200mg ***
Equivalent to Monacolin K 10mg ***
Lactobacillus plantarum LPLDL® 4x109 CFU** ***
Vitamin B3 4mg 25
*NRV - Nutrient Reference Value **Minimum of 4 Billion CFU at the expiration ***NRV not established
mol
and perhaps our relationship with Kappa continues behind the scenes
Additional research has further substantiated the link between vitamin K2 and heart health. Thies Ripcke, director of business development, North America, at Kappa Bioscience (Oslo, Norway), says the results of a new trial may soon provide new data suggesting another role for vitamin K2 as a heart health ingredient.
“In 2018, Kappa Bioscience supported a new independent research project with the goal of expanding our understanding of the link between vitamin K2 MK-7 and cardiovascular health,” Ripcke explains. “The AVADEC study set out to investigate the effects of Kappa Bioscience’s MK-7 solution, K2Vital Delta, in combination with vitamin D3, on calcium deposits in the aortic valve and coronary arteries.”
As of press time, the results of the AVADEC study weren’t publicly published. But Ripcke says the study will provide new data suggesting that MK-7 and vitamin D may slow the progression of coronary artery calcification.
https://www.nutraceuticalbusinessreview.com/news/article_page/Kappa_Biosciences_uses_Optibiotix_ingredient_to_improve_K2_offering/156252
mol
recent article here (3rd January 2023) with Zak commenting
https://www.nutritionaloutlook.com/view/heart-smarts-nutrition-researchers-unveil-new-benefits-of-natural-ingredients
Research has found that in addition to their effects on cholesterol levels, probiotics can influence the risk of coronary heart disease. Zac Sniderman, director of business development, North America, OptiBiotix Health (UK), says a recent study6 on the branded OptiBiotix Lactobacillus plantarum ingredient LPLDL showed that the ingredient can reduce non-HDL cholesterol and apolipoprotein B. This study, a randomized, double-blind, placebo-controlled pilot trial funded by OptiBiotix, assessed the effects of the L. plantarum on cholesterol in 16 adults with high cholesterol. The subjects were randomly assigned to receive either 4 billion CFU of L. plantarum per day, or a placebo, for six weeks, followed by a three-week washout period. The study found that six weeks of L. plantarum consumption decreased total cholesterol by 34.6%, LDL cholesterol by 28.4%, non-HDL cholesterol by 17.6%, and apolipoprotein B by 28.6%.
“More recently, OptiBiotix has been investigating the effects of novel prebiotics, such as xylo-oligosaccharides (XOS), with our probiotic strain LPLDL,” Sniderman adds. “Our research has shown that when XOS is combined with certain probiotic strains, there is an increased rate of growth activity in the gut, accentuating the health benefits.”
there is also another US company using a different strain
Sid Shastri, director of research and business, probiotics division, at Kaneka Americas Holding Inc. (Pasadena, TX), says Kaneka began developing probiotics for heart health over 10 years ago. Kaneka’s internal studies have shown that Floradapt Cardio, the company’s patented heart health probiotic ingredient, can reduce LDL cholesterol and triglyceride levels. Floradapt Cardio is a blend of Kaneka’s proprietary Lactobacillus plantarum KABP-011, L. plantarum KABP-012, and L. plantarum KABP-013 strains. The blend contains 1.2 billion CFU per 100-mg capsule.
More recently, a 2021 randomized, double-blind, placebo-controlled trial5 examined the effects of Floradapt Cardio and red yeast rice extract (containing 10 mg of monacolin K) on LDL cholesterol and other biomarkers of blood lipid concentration in 39 subjects with high total cholesterol (200 mg/dL or more). Subjects were randomly assigned to receive either one capsule of Floradapt Cardio per day, or a matching placebo, for 12 weeks. The subjects were examined for body weight, BMI, body fat percentage, blood triglycerides, LDL cholesterol, and total cholesterol at baseline and after 6 and 12 weeks.
mind as we know the FDA have banned their use and the EU is considering same
https://www.nccih.nih.gov/health/red-yeast-rice
Yes; registration is taking a while to come through! I have to admit I was originally going to cash in but will hold now; some great noise being made around PBX. Hope people annoyed with OPTI don't cash out; that said if PBX is doing well and OPTI owns so much of it; seems not worthwhile to do that.
Agree potential there but many are going to sell soon as it is free potential cash and probably why this interview was done really (Time)
https://lemminginvestor.substack.com/publish
2 PBX articles this week.
If this is genuinely 21.5 to sell then I'm pretty happy! Was expecting a bit of a kick downwards first thing as the shares came online although I think it'd be silly to sell now with some really promising news coming out! Looks like this is one section of the OPTI/SBTX bundle that is actually doing really well.
Showing as sells here? No idea what’s going on…
But at least there’s some movement today.
Well, that’s two I’ve counted so far and they must be buys as the bid offer spread has increased…
Interesting update
Still no sign of live shares though in my account.
GLA
The Company believes that LPLDL® will be the first probiotic strain ever to be registered in Brazil for cardiovascular health, with first-mover benefits and strong interest from the pharmaceutical industry.
c. New product launches in Hong Kong, Germany and on TMAll in China. A number of these from companies who have already placed orders with delivery in 2023.
d. One or more agreements with large US partners creating the opportunity for substantive revenue growth. This will be supported by the expansion of our CholBiome® range with a phytosterol-containing product with US health claims.
e. Continued strong growth in e-commerce sales with anticipated revenues of £250K to £500K
5. Scientific Update: The Company continues its scientific studies to support sales and marketing efforts with scientific presentations and publications and developing the product pipeline. This can be through exploring new probiotic strains and/or extending the applications and use of LPLDL®. Current studies include human studies investigating the impact of LPLDL® on sleep, stress, and anxiety, and the reduction of cholesterol in coeliac disease. Sleep aids and stress management products are the fastest growing category within healthcare (Goldstein Market Intelligence, 2020) and this is another step in extending the range of applications for our scientifically and clinically proven products into large growing markets where there is an unmet clinical need. The Company has had three abstracts accepted for presentation as posters and/or oral presentations at ProBiota in February 2023.
6. Corporate: The Company aim will continue to work with AQUIS and explore opportunities on other markets, including AIM, to increase liquidity in ProBiotix shares.
The Company sees 2023 as a year of opportunity and continued growth and operational profitability, with a focus on commercialising products across more territories, particularly the USA with larger partners, and increasing the proportion of final product to ingredient sales to partners and via our e-commerce platform. This will be supported by a developing product pipeline with new probiotic strains and extending the applications and use of LPLDL® into new areas, all supported by strong science and human studies.
The scale of the market opportunity in probiotics is large, particularly outside the traditional gut health and health and wellbeing markets, where growth is slowing. This is increasing interest in ProBiotix and its products from larger partners looking to sustain future growth. The proven safety and efficacy of our products, the substantial scope for expansion of our range and geography, and the appointment of a proven commercial industry leader, allow us to look to 2023 with confidence and enthusiasm.
Stephen O'Hara, Director of ProBiotix, commented: "The recruitment of Steen Andersen as CEO to ProBiotix brings in an established industry figure to lead the Company into ts next stage of deve
https://www.aquis.eu/aquis-stock-exchange/for-investors/announcements?view_news_id=3888388
ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, provides an update on recent scientific and commercial activities: -
1. Commencement of employment of Steen Andersen as Chief Executive Officer (CEO) of ProBiotix: The Company announces that Steen Andersen joined ProBiotix as CEO on 2 January 2023. Steen brings 30 years' experience in building businesses in the probiotics industry, having been President of Deerland Probiotics and Enzymes, President and CEO of Bifodan, President and CEO of Fluxome, and Vice President of Human Health at Chr. Hansen. ProBiotix believes that Steen's industry reputation, network of contacts, experience and track record of growing sales and profitability will help accelerate the growth and recognition of ProBiotix into 2023 and beyond.
2. Commercial Activity 2022: The Company reports that 2022 has been a year of continued strong growth for ProBiotix with existing customers increasing sales, new customers in Belgium, USA, Spain, South America, Hong Kong, Israel and Germany contributing revenues for the first time, e-commerce sales doubling, and growing sales in dairy. A detailed trading update will be provided in the next few months.
3. Growing product range in dairy: The Company reports growing interest in the use of LPLDL® in dairy following the launch of Yo-Life® with our partner Granja Pocha in Uruguay. The launch of Yo-Life® represented a significant milestone for the Company as it extended the use of LPLDL® into functional dairy foods with a health claim ("helps reduce cholesterol"). Following the launch of Yo-Life®, we have seen increased use of LPLDL® in other dairy products with the launch of spreadable cream, a drinking yogurt, a Greek yoghurt starter culture in the USA, and a creamy herb cheese in Canada. Of particular interest is the increased evaluation and use of LPLDL® by large partners looking at plant based alternatives to dairy, where LPLDL® appears to improve the taste and texture of plant based dairy alternatives in addition to cholesterol reducing benefits. The use of LPLDL® in food products such as dairy/dairy alternatives is of strategic interest as it opens up markets where volumes and sales are significantly higher than the dietary supplement industry, with potential for substantive growth.
4. Commercial Activity 2023: The Company reports early indications for 2023 show another year of strong growth including the potential for:-
a. Extension of product ranges and territories with the Company's two largest partners, AlfaSigma and Seed Health.
b. The launch of CholBiome® products in Brazil with Ayalla, following an 18 month registration period, with a health claim for cardiovascular health.
DS01 will move to the top of the charts if the phase 2 clinical study results for IBS prove favourable once published
https://ichgcp.net/clinical-trials-registry/NCT04598295
For 2023
Seed DS-01 in at number five
https://www.healthcanal.com/nutrition/best-vegan-probiotic
mol
Nowt today on aquis exchange so far - nothing since 23 Dec as previously noted
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=PBX
mol
Not much action via this link:
https://www.hl.co.uk/shares/shares-search-results/p/probiotix-health-plc-ord-gbp0.05
Okidoky then….
Just a waiting game.
Thanks for the update.